News
![2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More): https://g.foolcdn.com/editorial/images/758458/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMThCYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2f97aae14d95275494c83aa114d318da3ab3a6f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=us)
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been
![1 Super Value Stock Down 30% to Buy in 2024: https://g.foolcdn.com/editorial/images/760045/telecom-worker-woman-industrials-5g-tech-11.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG9CYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--05ad42ea98e3aff110eccaaaaeb2ff69031589f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/telecom-worker-woman-industrials-5g-tech-11.jpg?locale=us)
1 Super Value Stock Down 30% to Buy in 2024
There's a disconnect between AT&T (NYSE: T) the stock and AT&T the company. While investors have punished the telecom stock over the past few years, sending shares down about 30% since the start of
![EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
![EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS) : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelB3SXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--521237387ec8207326f44117d145b81c1391bc28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_color_high_res.jpg?locale=us)
EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
![EQS-News: Evotec announces CEO transition: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
EQS-News: Evotec announces CEO transition
![EQS-Adhoc: Evotec announces CEO transition: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
EQS-Adhoc: Evotec announces CEO transition
![Could Abbott Laboratories Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/759413/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFlBYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c501f264bb4a24058d15bbe7086024d7423928b7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=us)
Could Abbott Laboratories Stock Help You Become a Millionaire?
Abbott Laboratories (NYSE: ABT) is a longtime leader in the healthcare industry. The medical device specialist has been around for decades, delivering solid returns to its loyal shareholders
![1 Concerning Trend for AbbVie Investors to Keep an Eye On: https://g.foolcdn.com/editorial/images/759502/worried-investor-looking-at-their-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3YvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b5b2b825f9251b93c2426f0fad667dc28b640084/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/worried-investor-looking-at-their-laptop.jpg?locale=us)
1 Concerning Trend for AbbVie Investors to Keep an Eye On
AbbVie (NYSE: ABBV) is a top pharmaceutical company with a broad mix of products in its portfolio. It also pays an attractive dividend, which yields 4% -- that's more than twice the S&P 500 average
![2 Biotechs That Could Get Bought Out in 2024: https://g.foolcdn.com/editorial/images/759923/ma.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGIvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2ad215804456d8de2c0350da536fdf927253365d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ma.jpg?locale=us)
2 Biotechs That Could Get Bought Out in 2024
Big pharma is facing another round of major patent expirations. Before the decade's end, Bristol Myers Squibb (BMS) will lose exclusivity for the megablockbuster blood thinner Eliquis as well as its
![3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years: https://g.foolcdn.com/editorial/images/759497/investor-pointing-at-a-chart.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1QvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--67382628d56f1cd5b88418bfc37a7a775ffbcd16/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-pointing-at-a-chart.jpg?locale=us)
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
Growth stocks get the designation because they have the potential to generate life-changing gains for investors. Some even do so in a relatively short time frame. Finding proper growth stocks
![2 Biotech Stocks You Can Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/758457/patient-talking-with-a-physician.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFgrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--92576b9790ca0eef3425f8288e3ae46891a42509/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-talking-with-a-physician.jpg?locale=us)
2 Biotech Stocks You Can Buy and Hold for the Next Decade
There are many ways to grow one's wealth over a decade, but few are as accessible as investing in stocks. Even with a relatively modest sum, picking the right investments and letting time and
![3 Top Dividend Growth Stocks to Buy in 2024: https://g.foolcdn.com/editorial/images/759630/hands-behind-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmorYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--10da018f2a5f129db1d516c0106dc4e1285fe21a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/hands-behind-head.jpg?locale=us)
3 Top Dividend Growth Stocks to Buy in 2024
Dividends are nice. But do you know what's even nicer? Fast-growing dividends. That's especially true with inflation eroding the purchasing power of your money.
The good news for income investors is
![Why Eli Lilly Stock Could Start Off 2024 With a Bang: https://g.foolcdn.com/editorial/images/759509/businessperson-giving-a-presentation.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTcrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8554bdce82501ae281060c11459cf6f858413979/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessperson-giving-a-presentation.jpg?locale=us)
Why Eli Lilly Stock Could Start Off 2024 With a Bang
Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550
![Prediction: These 3 Stocks Will Soar in 2024: https://g.foolcdn.com/editorial/images/759462/cheering-person-with-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUgrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--256d4d4f9f904156d9bd330a6249b02a2281ccf7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cheering-person-with-laptop.jpg?locale=us)
Prediction: These 3 Stocks Will Soar in 2024
No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen.
Three Fool.com contributors have done just that. Here's
![Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio: https://g.foolcdn.com/editorial/images/759353/photo-of-las-vegas-strip.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0wrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--da64e554950ec0b3bd4e11c75d1cb85691a82437/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/photo-of-las-vegas-strip.jpg?locale=us)
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
Inflation is arguably the top economic story of the last couple of years. Indeed, consumer purchasing power is down 16% since the beginning of 2020. That means $1,500 would only buy $1,260 worth of
![2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics: https://g.foolcdn.com/editorial/images/759577/scientist-researcher-microscope-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2I5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--105511a604c129d2b0fc60e6f1c9b87eee507366/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-researcher-microscope-lab.jpg?locale=us)
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex
![4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024: https://g.foolcdn.com/editorial/images/759627/cash-money-hundred-dollar-bills.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTc5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2e379a48846e0331970b305ca853add31aba0f82/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cash-money-hundred-dollar-bills.jpg?locale=us)
4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024
Dividend stocks can be incredible investments. They've historically outperformed the market over the long term. The best returns have come from companies that routinely increase their dividends.
![3 Stocks That Could Be Monster Winners in 2024: https://g.foolcdn.com/editorial/images/759574/chart-asian-woman-pointing.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVg5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b9029c295d8367b56c2c4aac482f1299ec4c13a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chart-asian-woman-pointing.jpg?locale=us)
3 Stocks That Could Be Monster Winners in 2024
Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.
Three Motley Fool contributors think
![2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now: https://g.foolcdn.com/editorial/images/759427/investor-smiling-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUQ5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--55e6496049fb56259fa29d6c94b05fd5ad502770/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-smiling-computer.jpg?locale=us)
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now
While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable
![EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelB3SXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--521237387ec8207326f44117d145b81c1391bc28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_color_high_res.jpg?locale=us)
EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
![Why Coherus BioSciences Stock Jumped Today: https://g.foolcdn.com/editorial/images/759608/medicine-pills-fda-approval-stamp-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOG44YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--332958987267e600458c4134f3e0e3ccff14e9a0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medicine-pills-fda-approval-stamp-1.jpg?locale=us)
Why Coherus BioSciences Stock Jumped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) are up 19.7% as of 3:20 p.m. ET Thursday after the U.S. Food and Drug Administration (FDA) approved Udenyca OnBody, the company's on-body injection
![3 Things About Sarepta Therapeutics Every Smart Investor Knows: https://g.foolcdn.com/editorial/images/759359/biotech-pharma-researchers-talk-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4e20f07bb520e5b3402232bdf46d1993bc265b18/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/biotech-pharma-researchers-talk-lab.jpg?locale=us)
3 Things About Sarepta Therapeutics Every Smart Investor Knows
Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on
![Best Dividend Stock 2024: Ford Stock vs. AT&T Stock: https://g.foolcdn.com/editorial/images/759482/ev-electric-truck-f-150-lightning-lariat-source-ford-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUw4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e39be61d06608e21e9067c8c4816a6a932b99ae4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ev-electric-truck-f-150-lightning-lariat-source-ford-1.jpg?locale=us)
Best Dividend Stock 2024: Ford Stock vs. AT&T Stock
Fool.com contributor Parkev Tatevosian compares Ford (NYSE: F) and AT&T (NYSE: T) on vital financial metrics to determine the better dividend stock to buy for 2024.
*Stock prices used were the
![3 Reasons to Buy AT&T Stock in 2024: https://g.foolcdn.com/editorial/images/759383/small-retail-store-with-_att-logo_att.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEQ4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--66a303c31cbdf63f84dfb49dea7c492c2d77cd77/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/small-retail-store-with-_att-logo_att.jpg?locale=us)
3 Reasons to Buy AT&T Stock in 2024
Telecom giant AT&T (NYSE: T) is vastly underperforming the S&P 500 in 2023. With just a few trading days left in the year, AT&T stock is down nearly 10% year to date while the S&P 500 has gained
![Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?: https://g.foolcdn.com/editorial/images/759358/scientist-with-head-down.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGo4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2bc1f2f2e1695fa2eacaca3299f5a4a1b555fff7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-with-head-down.jpg?locale=us)
Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?
You might call it a "Pfizzle."
In late 2021, Pfizer (NYSE: PFE) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.
It followed